Labcorp Holdings (LH)

Labcorp’s test menu spans about 5,000 assays, from standard blood, urine, and chemistry panels to more specialised diagnostics in oncology, genetics, women’s health, infectious disease, and chronic-condition management. This breadth is central to its competitive position: routine testing provides scale and recurring volume, while advanced and esoteric tests offer higher clinical complexity and support demand from specialists and health systems.

The company competes in an industry where efficiency, payer relationships, logistics, automation, and turnaround times matter. Its national laboratory infrastructure allows specimens to be collected locally and routed through regional and specialty labs, helping Labcorp serve both everyday primary-care needs and more complex diagnostic workups. It also benefits from the long-term trend toward earlier disease detection, personalised medicine, and the growing use of genomic and molecular testing.

For investors, Labcorp represents exposure to the healthcare services market rather than drug or device manufacturing. Its performance is tied to testing volumes, reimbursement rates, healthcare utilisation, and the ability to manage laboratory costs at scale. The company’s role in the medical system is practical and essential: it converts patient samples into clinical information that guides care decisions.